[{"orgOrder":0,"company":"ChemRar","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia Grants Temporary Approval for Avifavir to Treat Covid-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Small molecule","productStatus":"Approved","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"ChemRar"},{"orgOrder":0,"company":"ChemRar","sponsor":"Russian Direct Investment Fund (RDIF)","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"RDIF and ChemRar Exceed Target Production of Avifavir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"ChemRar"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Mexico Eyes October Start for Gamaleya Research Institute of Epidemiology and Microbiology's Phase 3 Trials of Russian Coronavirus Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Gamaleya Institute Confirms 1st Interim Data Analysis of the Sputnik V Vaccine Against Covid-19 Phase III Clinical Trials Show 92% Efficacy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia\u2019s Sputnik COVID-19 Vaccine Has 91.4% Efficacy After 28 days, New Interim Data Show","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russia's Sputnik Vaccine Applies for Phase 3 Study in Brazil","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"UAE Starts Trials of Russia's Sputnik V Coronavirus Vaccine as Cases Rise","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EMA Starts Rolling Review of the Sputnik V COVID-19 Vaccine Share","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V Demonstrates 97.6% Efficacy According to Analysis of Data from 3.8 Million Vaccinated Persons in Russia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Single Dose Vaccine, Sputnik Light, Authorized for Use in Russia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"An Open, Non-Randomised, Phase 1\/2 Trial on The Safety, Tolerability, and Immunogenicity of Single-Dose Vaccine \u201cSputnik Light\u201d For Prevention of Coronavirus Infection in Healthy Adults","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"The Gamaleya National Center of Epidemiology and Microbiology","sponsor":"Russian Direct Investment Fund","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V Demonstrates Strong Protection Against Omicron Variant, With Over 2 Times Higher Virus Neutralizing Activity Compared to the Pfizer Vaccine According to a Unique Independent Comparative Study Conducted by the Spallanzani Institute in Italy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"January 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"The Gamaleya National Center of Epidemiology and Microbiology"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"The Gamaleya National Center of Epidemiology and Microbiology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"RDIF Confirms Sputnik V COVID Vaccine\u2019s Efficacy","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Russian Direct Investment Fund"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"The Gamaleya National Center of Epidemiology and Microbiology","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Argentina has Registered the Sputnik V Vaccine Based on Russian Clinical Trial Data","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Vaccine","graph2":"Russian Direct Investment Fund"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russian Direct Investment Fund Reports that Ministry of Health of the UAE Has Approved the Use of Sputnik V Vaccine","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Russian Direct Investment Fund"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Single-Dose Sputnik Light Vaccine Approved for Use in Nicaragua","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Russian Direct Investment Fund"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik Light Vaccine Demonstrates 78.6-83.7% Efficacy Among the Elderly in Argentina","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Russian Direct Investment Fund"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Russian Direct Investment Fund: Single-Dose Sputnik Light Vaccine aPproved for Use in the Republic of the Congo","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Russian Direct Investment Fund"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V Demonstrates 94.3% Efficacy and High Safety Profile During the Vaccination Campaign in Bahrain","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Russian Direct Investment Fund"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V Vaccine Demonstrates a High Level of Safety in the Vaccination Course","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Russian Direct Investment Fund"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V Vaccine Elicits High IGG Antibodies and Neutralizing Antibodies Titers, Reports Argentina Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"July 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Russian Direct Investment Fund"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Study Published in the Journal EClinicalMedicine on the Efficacy of the \"Sputnik Light\" Vaccine Among the Elderly in Argentina","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Russian Direct Investment Fund"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V Demonstrates 94.8% Efficacy Against COVID During the Vaccination Campaign in San Marino","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Russian Direct Investment Fund"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V And Sputnik Light Vaccines Authorized in Cambodia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Vaccine","graph2":"Russian Direct Investment Fund"},{"orgOrder":0,"company":"Russian Direct Investment Fund","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Sputnik V vaccine Granted Full Permanent Approval in Russia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Vaccine","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Vaccine","graph2":"Russian Direct Investment Fund"},{"orgOrder":0,"company":"Binnopharm Group","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Binnopharm Group Enters Into Agreement to Acquire Two Anti-Bacterial Brands From Dr. Reddy\u2019s in the Russia & CIS Region","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"RUSSIA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Binnopharm Group"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Deal will allow Binnopharm Group to acquire anti-bacterial medicines under the Ciprolet® and Levolet® brands from Dr. Reddy’s in Russia, Uzbekistan and Belarus. The portfolio includes various dosage forms such as tablets, solution for infusions and eye drops.
Sputnik V and Sputnik Light are based on a safe and effective human adenoviral vector platform and have not been associated with rare serious adverse events following vaccination, such as myocarditis or pericarditis.
Sputnik V (Gam-COVID-Vac), shows significantly smaller (2.6 times) reduction of virus-neutralizing activity against Omicron as compared to the reference Wuhan variant than Pfizer vaccine (8.1-fold reduction for Sputnik V in contrast to 21.4-fold reduction for Pfizer vaccine).
The trial with involvement of 6000 participants would help to further investigate whether single-dose “Sputnik Light” vaccine could be a good choice for revaccination providing effective protection from SARS-CoV-2 infection in persons with pre-existing immunity.
Cambodia has become the 71st country in the world to register the Russian vaccine. Sputnik V was granted an emergency use authorization. The one-shot Sputnik Light vaccine is based on the human adenovirus serotype 26, the first component of Sputnik V.
According to the study in the Province of Buenos Aires, the first component of Sputnik V (Sputnik Light) has shown 78.6-83.7% efficacy against COVID-19 in high-risk elderly subjects which is significantly higher than efficacy demonstrated by most two-component vaccines.
The efficacy of Sputnik V was measured based on the monitoring of COVID cases between 25 February and 23 August, 2021. Sputnik V is the most efficient vaccine against hospitalizations with COVID-19 in the country.
The research evaluates SARS-CoV-2-specific antibody responses after vaccination of 288 healthcare workers with Sputnik V in Argentina, measuring IgG anti-spike titers and neutralizing capacity after one and two doses among non-infected and previously infected individuals.
Real world data obtained during the vaccination of the population in a no. of countries besides San Marino, including Mexico, Argentina, Serbia, Bahrain, Hungary, UAE and others, demonstrates that Sputnik V is one of the safest and most effective vaccines against coronavirus.
An efficacy study of Sputnik V was conducted in Bahrain in accordance with WHO guidelines involving more than 5,000 subjects. Overall efficacy beyond 14 days after administering the second dose was estimated at 94.3%.